|1.||Shiffman, Mitchell L: 3 articles (10/2010 - 04/2007)|
|2.||Chun, Eric: 3 articles (10/2010 - 09/2009)|
|3.||Heise, Jamie: 3 articles (10/2010 - 09/2009)|
|4.||Yeh, Li-Tain: 3 articles (03/2005 - 08/2003)|
|5.||Arora, Sanjeev: 2 articles (10/2011 - 07/2007)|
|6.||Gish, Robert G: 2 articles (01/2010 - 07/2007)|
|7.||Halliman, Deanine G: 2 articles (01/2010 - 09/2009)|
|8.||Nelson, David R: 2 articles (09/2009 - 07/2007)|
|9.||Pockros, Paul J: 2 articles (09/2009 - 08/2009)|
|10.||McHutchison, John G: 2 articles (04/2007 - 05/2006)|
|1.||Chronic Hepatitis C
09/01/2009 - "These results suggest fixed-dose VRD given 600 mg BID is insufficient to treat patients with chronic hepatitis C; a weight-based dosing trial of viramidine is currently under way."
12/01/2008 - "Taribavirin for the treatment of chronic hepatitis C."
09/01/2009 - "A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results."
09/01/2009 - "The phase III Viramidine's Safety and Efficacy versus Ribavirin 1 (ViSER1) study randomized 972 treatment-naïve patients with chronic hepatitis C to fixed-dose VRD (600 mg BID) or weight-based RBV (1000 or 1200 mg/day), each given with peg-IFN alfa-2b at 1.5 microg/kg/week. "
08/01/2012 - "Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1."
10/01/2011 - "The dosing strategy of taribavirin favors concentration within the liver to reduce treatment-limiting rates of anemia but may be insufficient to prevent virologic relapse."
01/01/2010 - "Viramidine is associated with a lower incidence of anemia because of its liver-targeting properties. "
12/01/2008 - "Taribavirin may increase adherence to therapy for chronic HCV by reducing the need for dose reduction due to anemia. "
10/01/2010 - "The study aimed to determine if weight-based dosing of taribavirin (TBV), an oral prodrug of ribavirin (RBV), demonstrated efficacy comparable to RBV while maintaining its previously demonstrated anemia advantage with fixed dose administration. "
12/01/2008 - "A recent Phase II trial investigating early and sustained virological response showed no statistically significant differences between ribavirin 1000/1200 mg and taribavirin at 800-, 1200-, or 1600-mg dosing, while illustrating a lesser degree of anemia in 800- and 1200-mg dosing of taribavirin. "
10/01/2011 - "The literature suggests that weight-based dosing of taribavirin at 25 mg/kg demonstrates lower rates of hemolytic anemia with comparable rates of sustained virologic response (SVR) and is the optimum dose for further studies comparing the efficacy of taribavirin with weight-based dosing of ribavirin. "
10/01/2011 - "Taribavirin, a ribavirin prodrug, was designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the subsequent development of hemolytic anemia. "
06/01/2005 - "Elucidation of ribavirin and viramidine phosphorylation mechanism should shed light on their in vivo metabolism, especially the ribavirin-induced hemolytic anemia in erythrocytes."
11/01/2003 - "Viramidine is a liver-targeting prodrug of ribavirin with much less potential for hemolytic anemia. "
05/01/2006 - "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C."
10/01/2005 - "The minimum effective dose of viramidine in these studies ranged from 15 to 31 mg/kg/day, depending upon the virus infection, when administered twice daily for 5 days beginning 4 h pre-virus exposure. "
10/01/2005 - "While both compounds appear to have similar efficacy against influenza virus infections, when one considers the lesser toxicity, viramidine may warrant further evaluation as a possible therapy for influenza."
10/01/2005 - "Viramidine's efficacy was also seen against an influenza A/NWS/33 (H1N1) virus infection in mice, when the compound was administered in the drinking water, the minimum effective dose being 100 mg/kg/day. "
10/01/2011 - "The objective of the review is to evaluate the efficacy and safety of taribavirin as compared with ribavirin in the treatment of chronic HCV infections. "
11/01/2002 - "Viramidine, an analog of ribavirin is a broad-spectrum antiviral under development by Ribapharm (previously the R&D division of ICN Pharmaceuticals) for the potential treatment of viral infections . "
10/01/2011 - "Taribavirin in the treatment of hepatitis C."
01/01/2010 - "Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients."
03/01/2005 - "The current study was carried out to evaluate pharmacokinetic profiles of viramidine and ribavirin in patients (n = 8 per dose group) with compensated hepatitis C infection following oral dosing of viramidine (400, 600, or 800 mg bid for 4 weeks). "
03/01/2005 - "Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection."
10/01/2004 - "An investigational nucleoside analogue drug, viramidine, has recently emerged as a potentially safer alternative to ribavirin for the treatment of hepatitis C viral infection. "
|3.||ribavirin amidine (viramidine)
|5.||Interferon Alfa-2a (Interferon Alfa 2a)
|8.||Interleukin 1 Receptor Antagonist Protein (Anakinra)
|10.||Glucagon-Like Peptide 1 (GLP 1)